FirsthandHealth
medRxiv PreprintsInternational16 November 2026

Dual-platform plasma proteogenomics prioritizes GSTA1 and ARG1 as druggable cross-domain targets in cardiovascular-kidney-metabolic syndrome

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Background: Cardiovascular-kidney-metabolic (CKM) syndrome reflects shared pathophysiology across metabolic, renal and cardiovascular systems, yet circulating proteins with causal effects spanning multiple CKM domains remain unclear. We aimed to identify and prioritize cross-domain candidate proteins using an integrative, dual-platform plasma proteogenomic framework. Methods: We combined genetic causal inference, statistical colocalization, single-cell expression mapping, and structure-based druggability assessment. Cis-protein quantitative trait loci (cis-pQTL) instruments were derived from t
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.